NEO — NEOGENOMICS INC
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1077183 ·
Last close
$15.25
Market Cap
$1.97B
52W High
$20.15
52W Low
$7.07
ADV30
1,805,819
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 209,254,000 | 96,588,000 | -7,941,000 | -7,546,000 | 1,376,917,000 | 139,281,000 | 576,279,000 |
| Jun 2026 | 201,656,000 | 91,878,000 | -9,771,000 | 2,238,000 | 1,352,243,000 | 145,539,000 | 566,511,000 |
| Mar 2026 | 186,672,000 | 80,864,000 | -18,241,000 | -17,106,000 | 1,346,531,000 | 146,143,000 | 517,771,000 |
| Dec 2025 | 190,170,000 | 83,343,000 | -12,788,000 | -9,881,000 | 1,359,830,000 | 159,618,000 | 523,268,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,280,000
Investing CF
$-31,472,000
Financing CF
$2,324,000
CapEx
$-32,863,000
Dividends Paid
—
Buybacks
$-25,000,000
EPS Diluted TTM
$-0.25
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-456,220,000
Inventory
$25,500,000
Receivables
$213,410,000
ST Investments
$0
EBIT TTM
$-32,934,000
Pretax Income TTM
$-36,179,000
Interest Exp TTM
$3,245,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$787,752,000
EBITDA
$30,608,000
Free Cash Flow
$-17,242,124
Enterprise Value
$2,558,648,832
Total Cash
$139,280,992
Total Debt
$449,140,992
Shares Out
129,389,465
Trailing EPS
$-0.24
Book Value
$6.20
ROE
-3.9%
ROA
-1.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 727,332,000 | -88,128,000 | -108,025,000 | 1,359,830,000 | 523,268,000 | 836,562,000 | 5,230,000 |
| Dec 2024 | 660,566,000 | -85,448,000 | -78,726,000 | 1,638,038,000 | 735,699,000 | 902,339,000 | 7,023,000 |
| Dec 2023 | 591,643,000 | -96,648,000 | -87,968,000 | 1,681,229,000 | 739,692,000 | 941,537,000 | -1,953,000 |
| Dec 2022 | 509,728,000 | -153,107,000 | -144,250,000 | 1,740,034,000 | 742,011,000 | 998,023,000 | -65,993,000 |
TTM Snapshot
Revenues TTM
$766,295,000
NetIncome TTM
$-51,878,000
OpCashFlow TTM
—
Assets (Latest)
$1,352,243,000
Forward EPS
$0.33
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CPRI | Capri Holdings Ltd | $1.97B | $19.08 | — |
| EVT | Eaton Vance Tax-Advantaged Dividend Income Fund | $1.96B | $26.33 | — |
| LUNR | Intuitive Machines, Inc. | $1.96B | $11.05 | — |
| TBNGY | PT Bukit Asam Tbk/ADR | $1.96B | $4.25 | — |
| AVVSY | Avio S.p.A./ADR | $1.96B | $10.59 | — |
News headlines (Yahoo Finance, 1h cache)
Did Narrower Quarterly Loss Just Shift NeoGenomics Stock Investment Narrative?
2026-11-06 02:16 · Yahoo
NEO Q3 deep dive: product mix shift and margin expansion drive robust oncology testing growth
2026-11-03 07:57 · Yahoo
5 revealing analyst questions from NeoGenomics’s Q3 earnings call
2026-10-31 19:47 · Yahoo
NeoGenomics (NEO) Beat Q3 Expectations, Is The Stock Still Cheap?
2026-10-29 17:10 · Yahoo
What NeoGenomics (NEO) Said on Its Q3 Earnings Call
2026-10-29 05:04 · Yahoo
NeoGenomics (NEO) Q3 2026 Earnings Call Transcript
2026-10-29 04:13 · Yahoo
NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates
2026-10-28 22:30 · Yahoo
NeoGenomics: Q3 Earnings Snapshot
2026-10-28 20:59 · Yahoo
NeoGenomics’s (NASDAQ:NEO) Q3 2026 sales beat estimates
2026-10-28 20:26 · Yahoo
NeoGenomics Reports Third Quarter 2026 Results
2026-10-28 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.